PT

Palvella Therapeutics, Inc.

PVLA·NASDAQ

$115.42

+10%
HealthcareBiotechnology

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$1.37B
EPS-3.7100
P/E Ratio-31.11
Earnings Date08/13/2026

pvla

Accrued Expenses

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

PT

Palvella Therapeutics, Inc. Competitors Analysis of Accrued Expenses

PVLA · NASDAQ
CompanyAccrued Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
0.00
N/AN/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
0.00
N/AN/AN/A
0.00
N/AN/AN/A
SVRA logo
Savara Inc.
NASDAQ:SVRA
6.55M
31.2%6.6%10.4%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
3.20M
84.8%40.2%70.9%
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
PT

Palvella Therapeutics, Inc. Fair Value Envelope

PVLA · NASDAQ

Our analysis suggests that PVLA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $115.42, this represents a potential HIDDEN relative to our calculated worth for Palvella Therapeutics, Inc..

Intrinsic Value
Current Price: $115.42